Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII.
Open Access
- 1 August 1978
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 62 (2) , 223-234
- https://doi.org/10.1172/jci109120
Abstract
Radiolabeled human Factor VIII was used to study its survival in normals and patients with classic hemophilia, and to study the heterogeneity of Factor VIII; Purified Factor VIII was radiolabeled with 125iodine (125I-VIII) without loss of its structural integrity. The survival of 125I-VIII was studied in six normals and six hemophiliacs of whom four of the hemophiliacs had received transfusions with normal cryoprecipitate before the 125I-VIII infusion. No significant difference was observed between the disappearance of Factor VIII coagulant activity and radioactivity in these hemophiliacs. 125I-VIII in plasma showed a biphasic disappearance with an average t1/2 of 2.9 +/- 0.4 h (SEM) for the first phase and 18.6 +/- 0.7 h (SEM) for the second phase, respectively. The survival of 125I-VIII was similar comparing normals and hemophiliacs. The highest molecular weight forms of Factor VIII disappear more rapidly than the lower molecular weight ones. This was established by analysis of the fractions obtained by gel chromatography of plasma collected at several times after infusion and by analysis of the in vivo disappearance of three subfractions of Factor VIII. The fraction of 125I-VIII binding to platelets in the presence of ristocetin (containing the highest molecular weight forms of Factor VIII including the ristocetin cofactor) represented about 50% of the radioactivity present in plasma after infusion and showed a t 1/2 of 11.7 +/- 0.9 h (SEM) for the second phase. The fraction, which was recovered in cryoprecipitate of the recipient's plasma, represented about 90% of the initial radioactivity and showed a t 1/2 of 16.3 +/- 0.8 h (SEM) for the second phase. The fraction of 125I-VIII remaining in the cryosupernatant plasma (containing low molecular weight forms of Factor (VIII) showed a t 1/2 of 27.2 +/- 1.1 h (SEM). The first phase of the disappearance of 125I-VIII is caused in part by the disappearance of the highest molecular weight forms, which are possibly removed by the reticuloendothelial system.This publication has 37 references indexed in Scilit:
- HETEROGENEITY OF HUMAN FACTOR-VIII .1. CHARACTERIZATION OF FACTOR-VIII PRESENT IN SUPERNATANT OF CRYOPRECIPITATE1978
- Macromolecular factor VIII complex: functional and structural heterogeneity observed in von Willebrand swine with transfusion.Proceedings of the National Academy of Sciences, 1977
- Assay of F. VIII-Related Antigen in a Variant of von Willebrand’s Disease.Thrombosis and Haemostasis, 1977
- Infusion of Human and Canine Factor VIII in Dogs with von Willebrand's Disease: Studies of the von Willebrand and Factor VIII Synthesis Stimulating FactorsScandinavian Journal of Haematology, 1976
- STUDIES ON PROLONGED BLEEDING-TIME IN VONWILLEBRANDS DISEASE1976
- Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodiesAnalytical Biochemistry, 1966
- The Fate of Prothrombin and Factors VIII, IX and X Transfused to Patients Deficient in these FactorsBritish Journal of Haematology, 1963
- Observations on Plasma Banking and Transfusion Procedures for Haemophihc Patients using a Quantitative Assay for Antihaemophilic Globulin (AHG)*British Journal of Haematology, 1959
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTJournal of Biological Chemistry, 1951
- HEMOPHILIA. I. THE ABNORMAL COAGULATION OF THE BLOOD AND ITS RELATION TO THE BLOOD PLATELETSJournal of Clinical Investigation, 1936